Clinical Trials
35 trialsStudy of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
Providence Health & Services
Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
University of Arizona
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1
Cancer Research UK
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
Vanderbilt-Ingram Cancer Center
Testing the Addition of the Anti-cancer Viral Therapy Telomelysinâ„¢ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery
NRG Oncology
QoLATI
Rigshospitalet, Denmark
Using MC1R Genotype to Impact Melanoma Risk Behavior
H. Lee Moffitt Cancer Center and Research Institute
AM-003
University of Virginia
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
2019-004849-32
German Cancer Research Center
PEVOsq
UNICANCER
Study to Examine Lesions of the Skin Using Confocal Laser Microscopy
LMU Klinikum
OESOCiTy
Nantes University Hospital
Primary Tumor Burden Score:A Novel Staging Parameter for ESCC After nCRT
Fudan University
Apollo
Leiden University Medical Center
ALTER-E005
Jiangxi Provincial Cancer Hospital
Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma
University of Alabama at Birmingham
Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients
Blokhin's Russian Cancer Research Center
SHINE
McMaster University
Everolimus Versus Placebo in Head and Neck Cancer
University of Chicago
PET-CT for Squamous Cell Carcinoma (SCC) of the Neck Nodes Unknown Primary Malignancy
AHS Cancer Control Alberta
Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer
Masonic Cancer Center, University of Minnesota
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Memorial Sloan Kettering Cancer Center
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
Memorial Sloan Kettering Cancer Center
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
University of Kansas Medical Center
Safety Study of Modified Vaccinia Virus to Cancer
University of Pittsburgh
Study of Sorafenib/Cetuximab in Head and Neck Cancer
Duke University
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
Icahn School of Medicine at Mount Sinai
FOFACT
Cambridge University Hospitals NHS Foundation Trust
Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
A Study of Conventional 3D Radiation vs. Intensity-Modulated Radiation in Squamous Cell Cancer of the Head and Neck
AHS Cancer Control Alberta
Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center